Reduction of the Renal Radioactivity of 111In-DOTA-Labeled Antibody Fragments with a Linkage Cleaved by the Renal Brush Border Membrane Enzymes

The interposition of a cleavable linkage by enzymes on the renal brush border membrane constitutes a promising approach for reducing the renal radioactivity levels of radiolabeled low-molecular-weight antibody fragments and constructs (LMW Abs). Herein, we applied the molecular design to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-based reagents for radiotheranostic applications with trivalent radiometals. DOTA or a derivative thereof was conjugated to a Fab through an FGK linkage ([111In]In-DO3AiBu-Bn-FGK-Fab or [111In]In-DOTA-Bn-FGK-Fab). When injected into mice, both generated radiometabolites, [111In]In-DO3AiBu-Bn-F and [111In]In-DOTA-Bn-F, by the angiotensin-converting enzyme at similar rates. Both exhibited significantly lower renal radioactivity levels than a 111In-labeled Fab prepared by the conventional procedure ([111In]In-DOTA-Bn-SCN-Fab). The different elimination rates of each radiometabolite from the kidney significantly affected the renal radioactivity levels. [111In]In-DO3AiBu-Bn-FGK-Fab preferentially reduced the renal localization without impairing tumor accumulation. These findings would pave the way for developing a DOTA-based radiotheranostic platform for LMW Abs bearing cleavable linkers for renal brush border enzymes.

[1]  K. Kopka,et al.  Enzymological Characterization of 64Cu-Labeled Neprilysin Substrates and Their Application for Modulating the Renal Clearance of Targeted Radiopharmaceuticals. , 2023, Journal of medicinal chemistry.

[2]  T. Uehara,et al.  Synthesis and evaluation of a para-carboxylated benzyl-DOTA for labeling peptides and polypeptides. , 2022, Nuclear medicine and biology.

[3]  A. Scott,et al.  Radiolabeled Antibodies for Cancer Imaging and Therapy , 2022, Cancers.

[4]  T. Uehara,et al.  Copper-64-Labeled Antibody Fragments for Immuno-PET/Radioimmunotherapy with Low Renal Radioactivity Levels and Amplified Tumor-Kidney Ratios , 2021, ACS omega.

[5]  H. Hanaoka,et al.  Renal Handling of 99mTc-Labeled Antibody Fab Fragments with a Linkage Cleavable by Enzymes on Brush Border Membrane. , 2020, Bioconjugate chemistry.

[6]  F. Bénard,et al.  Evaluation of Met-Val-Lys as a Renal Brush Border Enzyme-Cleavable Linker to Reduce Kidney Uptake of 68Ga-Labeled DOTA-Conjugated Peptides and Peptidomimetics , 2020, Molecules.

[7]  Y. Arano.  Renal brush border strategy: A developing procedure to reduce renal radioactivity levels of radiolabeled polypeptides. , 2020, Nuclear medicine and biology.

[8]  Xiaoyuan Chen,et al.  Improving the Theranostic Potential of Exendin 4 by Reducing the Renal Radioactivity through Brush Border Membrane Enzyme-Mediated Degradation. , 2019, Bioconjugate chemistry.

[9]  T. Uehara,et al.  Preferential Cleavage of a Tripeptide Linkage by Enzymes on Renal Brush Border Membrane To Reduce Renal Radioactivity Levels of Radiolabeled Antibody Fragments. , 2018, Journal of medicinal chemistry.

[10]  R. Baum,et al.  Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. , 2018, The British journal of radiology.

[11]  Fredrik Y Frejd,et al.  Affibody Molecules in Biotechnological and Medical Applications. , 2017, Trends in biotechnology.

[12]  Jean-Mathieu Beauregard,et al.  Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  H. Hanaoka,et al.  (67/68)Ga-labeling agent that liberates (67/68)Ga-NOTA-methionine by lysosomal proteolysis of parental low molecular weight polypeptides to reduce renal radioactivity levels. , 2014, Bioconjugate chemistry.

[14]  D. Scheinberg,et al.  Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with 225Ac for α-Particle Radioimmunotherapy of Cancer , 2014, The Journal of Nuclear Medicine.

[15]  K. Herrmann,et al.  68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs , 2014, Annals of Nuclear Medicine.

[16]  Atsushi B. Tsuji,et al.  Therapeutic Efficacy of C-Kit-Targeted Radioimmunotherapy Using 90Y-Labeled Anti-C-Kit Antibodies in a Mouse Model of Small Cell Lung Cancer , 2013, PloS one.

[17]  S. Muyldermans,et al.  Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators. , 2012, Contrast media & molecular imaging.

[18]  H. Hanaoka,et al.  Facile synthesis and evaluation of C-functionalized benzyl-1-oxa-4,7,10-triazacyclododecane-N,N',N″-triacetic acid as chelating agent for ¹¹¹In-labeled polypeptides. , 2012, Bioorganic & medicinal chemistry.

[19]  Theresa M Reineke,et al.  Theranostics: combining imaging and therapy. , 2011, Bioconjugate chemistry.

[20]  Atsushi B. Tsuji,et al.  C-kit-targeted imaging of gastrointestinal stromal tumor using radiolabeled anti-c-kit monoclonal antibody in a mouse tumor model. , 2010, Nuclear medicine and biology.

[21]  A. Sherry,et al.  Effect of the regiochemistry of butyl amide substituents on the solution-state structures of lanthanide(III) DOTA-tetraamide complexes. , 2009, Inorganic chemistry.

[22]  T. Uehara,et al.  Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. , 2008, Advanced drug delivery reviews.

[23]  F. Wuest,et al.  An 86Y-labeled mirror-image oligonucleotide: influence of Y-DOTA isomers on the biodistribution in rats. , 2008, Bioconjugate chemistry.

[24]  S. Jurisson,et al.  Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3. , 2007, Nuclear medicine and biology.

[25]  H. Saji,et al.  In vitro system to estimate renal brush border enzyme-mediated cleavage of Peptide linkages for designing radiolabeled antibody fragments of low renal radioactivity levels. , 2005, Bioconjugate chemistry.

[26]  T. Saga,et al.  Renal metabolism of 3'-iodohippuryl N(epsilon)-maleoyl-L-lysine (HML)-conjugated Fab fragments. , 2001, Bioconjugate chemistry.

[27]  David M. Goldenberg,et al.  Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations , 1998, European Journal of Nuclear Medicine.

[28]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[29]  J. Riordan,et al.  Angiotensin-converting enzyme: new concepts concerning its biological role. , 1989, Biochemistry.

[30]  S. Ronca-Testoni,et al.  Direct spectrophotometric assay for angiotensin-converting enzyme in serum. , 1983, Clinical chemistry.

[31]  K. Endo,et al.  Design, synthesis, and evaluation of [188Re]organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levels. , 2007, Bioconjugate chemistry.

[32]  Stephen J Mather,et al.  Conjugation of chelating agents to proteins and radiolabeling with trivalent metallic isotopes , 2006, Nature Protocols.

[33]  H. Sakahara,et al.  Assessment of radiochemical design of antibodies using an ester bond as the metabolizable linkage: evaluation of maleimidoethyl 3-(tri-n-butylstannyl)hippurate as a radioiodination reagent of antibodies for diagnostic and therapeutic applications. , 1996, Bioconjugate chemistry.

[34]  J F Murray,et al.  Determination of sulfhydryl groups with 2,2'- or 4,4'-dithiodipyridine. , 1967, Archives of biochemistry and biophysics.